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SUMMARY  
The most commonly used test for monitoring heparin therapy is the activated partial 
thromboplastin time (aPTT). The performance of available aPTT reagents varies 
significantly. The aim of this study was to assess the suitability of dried aPTT reagents 
for the purpose of monitoring unfractionated heparin dose-response in diagnostic 
devices. Ten reagents were analysed in terms of their performance in liquid and in dried 
form after 24 h and 14 days. The ability to reduce the natural plasma clotting time (CT) 
and their sensitivity to heparin was assessed. The thrombin generation assay was the 
method of choice. All reagents resulted in significant reductions in CT. Liquids returned 
more rapid CTs in comparison to dried reagents. Most reagents were more sensitive to 
heparin in dried, rather than in liquid form. Dried reagents based on kaolin as a surface 
activator were notably more effective in achieving rapid CT, while reagents composed 
of silica and synthetic phospholipids were the most sensitive to heparin. Identification 
of the most suitable aPTT assay reagent for incorporation into a diagnostic device 
platform was achieved based on dried reagent stability and responsiveness to heparin.  
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INTRODUCTION 
There has been growing interest in the development of miniaturized, point-of-care 
diagnostic devices (Khandurina and Guttman, 2002). There is an increasing requirement 
for reliable point-of-care devices for monitoring the effect of drugs which regulate 
blood coagulation (Khan, 2009). This in turn leads to an increased demand for highly 
concentrated and optimized formulations of active ingredients capable of inducing a 
rapid clotting response in a low volume test sample. Since the first application of partial 
thromboplastin time (aPTT) for monitoring anticoagulant therapy (Struver and Bittner, 
1962), it has become the most popular test for heparin dose monitoring (Gawoski et al., 
1987) and is regarded as the most reliable and commonly used test (Kitchen et al., 1996) 
for heparin dosage adjustment in long term therapy and pre-thrombotic monitoring 
(Bowers and Ferguson, 1993). There have been several automated devices developed to 
monitor aPTT, e.g. the CoaguCheck
®
 Pro. In general, such devices contain dry 
formulations that selectively induce the clotting process. The accuracy and reliability of 
the results are highly influenced by the quality of the dried chemistry. There are a 
growing number of ready-to-use aPTT reagent kits available in liquid or lyophilized 
forms. A number of studies have identified that aPTT reagents vary significantly in their 
responsiveness to heparin (Kitchen et al., 1999, Banez et al., 1980). Different aPTT 
reagents often return different aPTT values with normal patient plasmas. There is an 
urgent need for the standardization of aPTT-based monitoring systems for heparin 
therapy in clinical settings (Poller et al., 1989, Kitchen et al., 1996). The varying 
responsiveness of aPTT reagents is dependent upon the composition of particular 
constituents of the formulation. These contain animal or plant extracts as sources of 
phospholipids (partial thromboplastin) combined with a surface activator such as kaolin, 
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celite, silica, ellagic acid, dextran sulphate or carrageenans. Negatively charged 
substances supported by phospholipids bring about the surface-dependent activation of 
factor XII which is the first step of the contact activation pathway leading to the 
eventual formation of the insoluble fibrin clot (Griffin and Cochrane, 1979). Both, the 
source and the concentration of phospholipids have been highlighted as important 
factors in assay behaviour, e.g. a decreased phospholipid concentration can lead to an 
increased heparin sensitivity of the reagent (Ts'ao et al., 1998, Kitchen et al., 1999). 
Stevenson et al. documented that the lipid phase concentration may differ by 300 times 
between some commercially available aPTT reagents (Stevenson et al., 1986). 
Advances in technology have led to the development of recombinant materials for use 
in coagulation assays. Such defined and reproducible materials might help to control the 
variation that exists within aPTT activated clotting response (Barrowcliffe and Gray, 
1981, Triplett, 1982). Several reports provide a detailed characterization of aPTT 
reagents (Stevenson et al., 1991, Kitchen et al., 1999, Martin et al., 1992). These are 
extremely informative sources of data on aPTT reagent composition and performance in 
clinical and laboratory settings. The differences in their sensitivity to heparin and lupus 
antibodies have been shown (Eby, 1997, Manzato et al., 1998). However, there is very 
little data regarding the use of available aPTT formulations for the purpose of diagnostic 
device development. Due to a wide variety of aPTT products with different 
formulations and physical characteristics, an assessment of the aPTT performance in 
dried form and its stability upon prolonged storage time was needed. Evaluation of the 
dried-surface reagents would allow selection of the most suitable activators to be 
incorporated into a coagulation monitoring assay. The effect of resolubilization and 
drying on their activity is of particular relevance.    
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The thrombin generation assay (TGA) was chosen as a tool for the comparison of the 
ability of aPTT reagents to reduce natural plasma clotting time (CT) by measuring the 
rate of thrombin generation (van Veen et al., 2008). This study includes a comparison of 
a variety of aPTT formulations in (i) liquid, (ii) 24 h dried and (iii) 14 days dried forms. 
These were analysed in terms of their ability to reduce plasma CT, stability upon 
prolonged exposure to ambient conditions and responsiveness to heparin. 
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MATERIALS AND METHODS 
Materials  
Ten aPTT reagents were studied (Table 1). All assays were performed using Hemosil 
plasma (0020003710, Instrumentation Laboratory, Italy/USA). The colorimetric 
thrombin substrate was H-D-Phenylalanyl-L-pipecolyl-L-arginine-p-
nitroanilinedihydrochloride (S-2238, Chromogenix, Italy/USA) and was prepared by 
dilution 1:4 with Tris.HCl pH 8.3. Calcium chloride (CaCl2) (100989) was from 
BioData (Netherlands/USA). Heparin sodium salt was from Sigma, Germany/USA 
(H0777-100KU), Greiner BioOne 96 well microassay plates (655096, Greiner BioOne, 
Germany) were used for all assays. All water was 18 MΩ or greater. 
  
Thrombin Generation Assay 
Assays were carried out using 96-well polystyrene microassay plates. Each test well (n 
= 5) contained 50 µL aPTT reagent, 50 µL plasma, 50 µL colorimetric substrate and 50 
µL 25 mM CaCl2. aPTT reagent was pre-incubated with plasma according to 
manufacturer recommendations. Subsequently, colorimetric substrate and CaCl2 were 
added. Measurement was started immediately after CaCl2 addition. The amount of 
generated thrombin was determined colorimetrically by measuring the release of p-
nitroaniline (pNA) from the chromogenic substrate on a Tecan Infinite M200 (Tecan 
Group Ltd., Switzerland) at 405 nm with measurements made every 30 s for 1 h. TGA 
assays yielded absorbance profiles which related to the generation of thrombin 
following activation of the intrinsic clotting cascade. A positive thrombin control was 
also included in every assay where aPTT reagent was replaced with 50 µL of thrombin 
at a concentration of 3 U/mL (Sigma-Aldrich Inc.). aPTT reagents were analysed in 
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both liquid and dried forms, with the latter being evaluated at 24 h and 14 days 
following drying. For drying, 50 µL of aPTT reagent were pipetted into the 96 well 
plates and left to dry under ambient laboratory conditions. The dried reagent was 
reconstituted in 50 µL of water prior to analysis. Thrombin generation profiles for dried 
reagents at 24 h and 14 days were compared to those for liquid controls. 
 
Reagents were analysed in terms of their sensitivity to heparin using spiked plasma 
samples. It has been shown that the response from ex vivo samples from patients on 
heparin therapy differs from in vitro plasma samples spiked with heparin (Jespersen et 
al., 1999, Van den Besselaar et al., 1990). However, heparin-spiked samples were used 
herein for the purpose of a performance comparison between reagents and not for the 
aPTT clinical reference standardization. Control plasma was spiked with heparin so that 
the final concentration in plasma was between 0 and 2 U/mL.  
  
Data Analysis 
The activity of the aPTT reagents was determined by their ability to reduce the natural 
plasma CT. Three methods of CT calculation were employed which were (i) the length 
of the lag time (LT), which was taken as the time prior to the occurrence of the 
thrombin burst (observed as a rapid increase in the measured absorbance) followed by a 
propagation phase (Wolberg, 2007), (ii) the area under the curve (AUC) and (iii) the 
time-to-peak (TTP). AUC was calculated from both raw (absorbance vs time) and 
differentiated (dAbs vs time) data. This reflects the total time for which thrombin exerts 
its enzymatic activity and is related to the endogenous thrombin potential. TTP was 
taken as the time point where the response profile reached a plateau and the increase in 
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absorbance ceased. This is related to initiation of thrombin production and propagation 
and corresponds to the time required for the available substrate to be utilized (Wolberg, 
2007). Analysis of these characteristic response profiles led to the determination of CT 
based on LT. CT values were related to heparin concentration and the resulting 
correlations provided useful information about the dry and liquid reagent sensitivity to 
heparin. Inter- and intra-assay variation (CV) was also determined. 
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RESULTS  
Clotting time extraction. Fig. 1 shows typical thrombin generation profiles for human 
plasma samples with and without activation by Cephalinex aPTT reagent. The thrombin 
generation profile of the blank control showed a LT greater than 1500 s, a rapid increase 
in absorbance and a plateau at about 2500 s. In most assays, corn trypsin inhibitor is 
added to prevent controls from clotting. However, as a control to assess the level of 
inter-assay variability, non-activated controls were used (Lo et al., 2005). The average 
control plasma LT for all assays was found to be 1943 s with a %CV of 15.6%. 
Addition of liquid Cephalinex aPTT reagent resulted in the rapid onset of the thrombin 
burst resulting in an indeterminate LT. The linear fluorescence response was reached at 
about 150 s, with the plateau being reached at approx. 200 s. In comparison, when 
reagent was dried, an increase in the LT of approx. 100 s was noted, which suggests that, 
for this reagent at least, drying did result in increased LT. However, there was little 
change in LT between 24 h and 14 days storage (LTs of around 300 s).  
 Fig. 1. 
 
Several methods were employed to correlate the TGA output with the change in CT 
following incubation with heparin as shown for aPTT-SP in Fig. 2. Heparin plays a role 
in the positive-feedback inhibition of thrombin (Beguin et al., 1988) and was used here 
to obtain prolonged clotting times. LT and TTP calculations resulted in similar 
correlations between CT values and heparin dosage. LT values were predictably lower 
than the TTP values by the difference in rise time for the thrombin burst. Both these 
parameters were prolonged with increased heparin concentration. The correlation was 
close to linear for both methods with R
2
 ≥ 0.986. Calculation of the area under the curve 
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(AUC) was not found to be a useful tool in CT determination. No correlation between 
calculated area values and heparin dose was found. LT was thus chosen as the most 
convenient and reliable way of determining the clotting time (CT) values and all further 
expressions of CT were based on this methodology. 
Fig. 2. 
 
Comparison of aPTT reagent activities in liquid and dried forms 
It has been established in many studies that commercially available aPTT reagents are 
effective for plasma CT reduction in their liquid form. However, an important parameter 
from the point of view of bioassay development is that reagents need to maintain their 
pro-coagulant properties upon long-term storage in a dehydrated state. The performance 
of aPTT reagents in their liquid and 24 h / 14 day dried forms was assessed by TGA 
according to their CT values (Fig. 3). 
Fig. 3. 
 
As expected, the performance of all aPTT reagents in their liquid forms was excellent. 
The liquid state was recommended by manufacturers to be used for plasma CT assays. 
CT values between 41 ±12.8 s for C.K. Prest 2 and 161 ±23.8 s for SynthASIL were 
obtained. In addition to comparisons of reagent activity in their liquid forms, the 
stability of the ready-to-use formulations was also assessed following drying and 
storage for 24 h and 14 days. Short term storage (24 h) did affect the activity of most 
reagents. CTs obtained for Platelin LS after 24 h were significantly prolonged, from 95 
±21.3 s in liquid to 468 ±15.9 s. CTs of dried reagents were at least twice as long as that 
for the equivalent liquid reagent: Alexin (85 ±7.1 s to 180 ±52.3 s), Cephalinex (110 
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±9.8 s to 288 ±55 s), C.K. Prest 2 (41 ±12.8 s to 96 ±15.9 s), aPTT-P (72 ±11.3 s to 218 
±19.3 s) and aPTT-SA (83 ±1.4 s to 184 ±24.2 s) for liquid and 24 h dried CTs, 
respectively. The only exception was aPTT-SP which proved to be perfectly stable after 
24 h yielding a shortened CT over the liquid form by approx. 10 s. 
 
In order to establish if the ability of the aPTT to activate clotting continued to 
deteriorate with prolonged storage, additional tests were performed after 14 days.  For 
all reagents, the CT values gradually increased with one exception; Cephalinex returned 
a CT of around 280 s for 24 h and 14 day measurements. The ability of Platelin LS and 
Alexin to reduce the plasma CT decreased dramatically to 1566 ±415.7 s and 850 
±130.7 s for 14 days Platelin LS and Alexin, respectively. The effect of reagent 
deterioration in the form of increased CT was expected to correlate with prolonged 
storage. Such reagents would not be considered as suitable candidates for a dried matrix 
of coagulation activators incorporated into a clot monitoring device. The addition of 
stabilizing buffers, preservatives or special storage conditions could be beneficial in the 
improvement of stability. However, the aim was to rapidly establish the activity of the 
dried ready-to-use reagents in order to select the most stable formulations. The effect of 
a diminished CT reduction was not as strongly manifest for the other eight reagents as it 
was for Platelin LS and Alexin. CTs were between 200 ±17.3 s for Dapttin to 438 
±135.2 s for aPTT-P.  
 
The ideal dried formulation not only had to reduce the plasma CT efficiently and be 
stable over a prolonged period of storage, but should also generate reproducible results 
and so inter- and intra- variability was a factor of importance. The within-run %CV was 
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maintained at ≤ 15% for all tested reagents (n = 5), while significant differences in the 
inter-assay variability (n = 3) was noticed. It was observed that reagents that were more 
affected by the storage time and conditions, resulting in a prolonged CT (in comparison 
to a liquid control) were also the least precise (highest %CV for between-assay 
variability). These were Platelin LS, Alexin, aPTT-P and aPTT-SA which yielded CTs 
of 1566 s (26.5%), 850 s (15.4%), 438 s (30.9%) and 314 s (40.5%) respectively. The 
remaining six reagents resulted in CTs < 300 s and %CV of less than 15%.  
 
Heparin sensitivity 
A striking variation in aPTT reagent sensitivity to thrombin inhibitors such as heparin 
has been documented (Greaves, 2004). Performance of aPTT reagents is highly 
dependent on the source and content of phospholipids as well as on the type and 
concentration of surface activator that is supposed to serve a large surface area for 
stimulation of kallikrein-like activity and initiation of coagulation. Several studies have 
reported the association of aPTT reagent composition with variations in clotting 
efficacy (Smeets et al., 1996, Neuenschwander et al., 1995) and responsiveness to 
anticoagulant dosage (Ip et al., 2001, Kitchen et al., 1996). Herein, the effect of the 
drying process and storage of the aPTT reagents was also evaluated for its effect on the 
response to heparin in the TGA. Such data is of great importance for the development of 
miniaturized systems for anticoagulant therapy monitoring. 
 
The effect of heparin addition (0 – 2 U/mL) on plasma CT triggered by all ten aPTT 
reagents in their liquid and dried forms was evaluated by TGA. Reagent sensitivity to 
heparin was assessed on the basis of the derived calibration curves. For example, the 
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results for aPTT-P are shown in Fig. 4. The correlation between plasma CT and heparin 
concentration was found to be linear for liquid and dried reagent with R
2 
> 0.98. 
However, the sensitivity to heparin was significantly different as evidenced by changes 
in slope. The 14 day form was found to be the most responsive to anticoagulant in 
which the CT increased by 392 s upon addition of heparin at 2 U/mL. In comparison, 
CT values for liquid and 24 h dried reagent were prolonged by 127 s and 150 s, 
respectively. The slope values illustrate the difference in heparin sensitivity: 62.2, 72.8 
and 193.6 s.mL.U
-1
 for liquid, 24 h and 14 days dried, respectively. However, it must 
also be taken into account that the base CT (0 U/mL heparin) was significantly 
increased due to drying from liquid (72 ±11 s) to 24 h (218 ±19 s) and 14 days (438 
±135 s), which suggested a significant deterioration in reagent activity. Therefore, 
regardless of higher heparin sensitivity, such a reagent would not be suitable. 
Furthermore, this reagent at 14 days yielded elevated %CV in comparison to the two 
other tested forms (31% in comparison to 16% and 12% for liquid and 24 h dried 
reagent, respectively).  
Fig. 4. 
 
Similar analyses were performed for the other reagents, the results of which are 
summarised in Table 2.  Addition of heparin resulted in the prolongation of CT for all 
tested reagents. Some of these were significantly affected by the presence of heparin in 
the sample, while others were less sensitive to its effect. The values obtained for liquid 
reagents increased from 41 – 161 s for 0 U/mL heparin to 102 – 286 s, 130 – 348 s, 
139 – 405 s and 199 – 810 s for 0.5, 0.75, 1 and 2 U/mL of heparin, respectively. CTs 
obtained for 24 h dried reagent changed from 88 – 468 s to 138 – 602 s, 208 – 737 s, 
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186 – 880 s and 258 – 946 s with an increased heparin concentration. 14 day dried 
reagents returned an increase in CT from 200 – 1566 s to 256 – 1517 s, 262 – 1439 s, 
280 – 1705 s and 369 s – > 1 h with increasing heparin concentrations, respectively. 
Although the issue of an increased base CT (0 U/mL heparin) occurred for all 14 day 
dried reagents, this form was generally the most responsive to heparin. The exceptions 
were Cephalinex, Dapttin and Alexin-HS for which the liquid form was the most 
sensitive to heparin and Platelin LS which was significantly affected by the drying 
process and 14 days of ambient storage resulted in the near complete loss of its potential 
to reduce plasma CT; CT values obtained for plasma with 0 – 1 U/mL heparin were 
1566 – 1640 s as compared to 1943 s for non-activated plasma. Generally, a trend of 
prolonged CT with increased heparin concentration was observed. However, there was 
great variation in the CT values for different aPTT reagents which suggested significant 
differences in reagent quality.  
 
The slope values in Table 2 indicate the differences in heparin sensitivity of the tested 
reagents both in liquid and dried forms. It should be noted that the slope values obtained 
for 14 day dried Platelin LS, Alexin and C.K. Prest 2 were quite high, but since no CT 
was obtained for 2 U/mL heparin and the correlation was based on only four data points, 
these reagents were excluded from the comparison of slope values for the 14 day dried 
reagents. SynthASIL was shown to be by far the best performing in this respect, 
yielding the highest slope values of 327.5, 312.1 and 443.1 s.mL.U
-1
 for liquid, 24 h and 
14 day dried forms, respectively. The non-heparinized plasma CTs of 161 ±24, 194 ±54 
and 293 ±43 s were prolonged to 810 ±36, 806 ±35 and 1170 ±94 s, respectively, upon 
addition of 2 U/mL of heparin. Such large differences in CT values (at least 600 s) 
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between non-heparinized and heparinized (2 U/mL) samples allowed good 
discrimination between samples of different heparin levels. The least responsive to 
heparin were aPTT-SA in liquid form (56.2 s.mL.U
-1
), Alexin in 24 h dried form (48.7 
s.mL.U
-1
) and Cephalinex as 14 day dried reagent (56.5 s.mL.U
-1
). These reagents 
returned insignificant CT differences when tested over a range of heparin concentrations. 
The use of these reagents in an anticoagulant monitoring device may result in the 
diminished discrimination between heparin doses. For the purposes of a reagent for use 
in a coagulation monitoring device, the activated CT is an extremely important factor 
determining the assay time. The shortest CTs were achieved for Dapttin with 95 ±1 s for 
non-heparinized plasma triggered with liquid reagent and 369 ±21 s for 2 U/mL heparin 
in plasma triggered with 14 day dried reagent. The longest CTs were obtained for 14 
day dried C.K. Prest 2, Platelin LS and Alexin for which an addition of heparin at 2 
U/mL resulted in an enormously prolonged CT with which it was not possible to extract 
a lag time. 
 
DISCUSSION 
Very good linear correlations between CT and heparin concentration were found for 
nine out of the ten tested reagents within the heparin range of 0 – 2 U/mL (R
2
 ≥ 0.83). 
Platelin LS was the only reagent on which the drying process had a dramatic negative 
impact resulting in significant loss of activity. High variation and no correlation with 
increased heparin concentrations were also found for the 14 day dried samples (R
2
 = 
0.02). Even though most of the reagents tested responded to addition of heparin by 
returning prolonged CTs, the deterioration of control clotting values (base CT) also had 
to be taken into account when selecting a stable, dry formulation which was responsive 
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to heparin. Among several methodological factors influencing the aPTT performance, 
the reagent composition is one of the most commonly cited (Manzato et al., 1998, 
Shetty et al., 2003, Wojtkowski et al., 1999). The available surface area of the 
negatively charged surface activators might be reduced due to dehydration following 
drying. The surface activation may be influenced by the type of activator used. Drying 
processes may have influenced the orientation and distribution of phospholipids. Some 
classes of phospholipids are of particular importance, and depending on their ratios and 
the total concentration of lipids, clotting can be promoted or inhibited (Slater et al., 
1980, Comfurius et al., 1994). Liquid reagents containing phospholipids derived from 
rabbit brain cephalin (C.K. Prest 2, aPTT-P, aPTT-SA and Alexin) returned the shortest 
CTs varying between 41 – 85 s. However, their ability to reduce plasma CT was 
significantly impacted by the drying process. The chicken and porcine-derived 
phospholipids used in Platelin LS gave an extremely prolonged CT in dried form (up to 
1566 s for 14 days dried reagent). APTT-SP (silica and synthetic phospholipids) was the 
only reagent for which the absolute CT did not increase after 24 h following drying. 
However, prolonged storage under ambient conditions did result in the reagent’s 
eventual deterioration. Another reagent which performed reasonably well was 
Cephalinex (containing silica activator and rabbit brain phospholipids). Despite the fact 
that the 24 h drying did influence the reagent’s ability to shorten plasma CT, the long 
term storage did not seem to affect its activity. However, Cephalinex was shown to be 
less sensitive to heparin than aPTT-SP in all three tested forms.  
 
It has been also shown that the type and concentration of surface activator plays a major 
role in the effectiveness of aPTT reagents (Marlar et al., 1984). Reagents based on 
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kaolin, (C.K. Prest 2) or kaolin/sulfatides (Dapttin) were shown to return rapid CTs in 
all three tested forms, not exceeding 100 s for liquid, 130 s for 24 h dried and 300 s for 
14 day dried forms. They were always among the five reagents with the shortest CTs. 
The combination of traditionally-used kaolin and rabbit brain cephalin extract (C.K. 
Prest 2) seemed to achieve rapid CTs. However, it should be taken into account that the 
use of insoluble particulates such as kaolin or silica for automated devices employing 
photo-optical detection may be problematic. The use of a soluble ellagic acid or a 
mixture of low concentration insoluble activators such as kaolin and sulfatides i.e. 
Dapttin (Moritz and Lang, 1995) may be a solution for devices based on optical 
detection systems.  
 
Although the reasons for the variable heparin sensitivity of the tested aPTT reagents 
have not been determined, the nature of surface activator and lipid composition seem to 
play a major role. The relationship between aPTT reagent lipid composition and heparin 
sensitivity was thoroughly investigated by Kitchen et al. (1999). Van den Besselaar et al. 
(1997) described a method of aPTT formulation preparation consisting of colloidal 
silica and synthetic phospholipids and suggested that the synthetic reagents should form 
a foundation for aPTT standardization of heparin therapeutic control. In fact, in our 
study, synthetic phospholipid-based reagents (SynthASIL and aPTT-SP) performed 
extremely well in terms of both heparin response and dried reagent stability. Additional 
benefits of such homogeneous materials based on synthetic phospholipids includes 
minimized batch-to-batch variability which leads to improvements in test CVs (Okuda 
and Yamamoto, 2004). Both aPTT-SP and SynthASIL which are both based on 
synthetic phospholipids and silica and are both manufactured by Hemosil, were 
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identified as promising candidates for incorporation into point of care diagnostic device 
platforms as dried reagents.  
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TABLES 
 
Table 1. Panel of aPTT reagents including the manufacturers and the composition
*
. 
Reagent Producer Surface Activator Source of 
phospholipids
APTT-SP Hemosil Colloidal silica Synthetic
Cephalinex BioData Microsilica Rabbit brain
SynthASIL Hemosil Colloidal silica Synthetic
Platelin LS BioMerieux Micronized silica Porcine + chicken
C. K. Prest 2 Diagnostica Stago Kaolin Rabbit brain
Dapttin Technoclone Synthetic kaolin+sulfatides Unknown
Alexin AMAX / Trinity Biotech Ellagic acid Rabbit brain
Alexin-HS AMAX / Trinity Biotech Ellagic acid Rabbit brain + soy
APTT-SA Helena BioSciences Ellagic acid Rabbit brain
APTT-P Biopool Magnesium-aluminium-silicate Rabbit brain  
*
Data is according to available manufacturer’s information. 
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Table 2. aPTT reagents in liquid and dried forms (24 h and 14 days) characterized in 
terms of their heparin dose sensitivity (slope), normal derived CT (intercept), linear 
correlation with heparin from 0 to 2 U/ml (R
2
), maximum standard deviation (SD) and 
maximum percentage coefficient of variation (CV). 
 
Reagent Form Slope [s.mL.U
-1
] Intercept [s] R
2
Max. SD [s] Max. CV [%]
Liquid 113.6 107.2 0.99 48 33
24 h 84.0 96.2 0.99 63 44
14 days 134.3 289.2 0.96 96 20
Liquid 65.5 117.3 0.98 23 9
24 h 57.8 261.6 0.83 68 22
14 days 56.5 284.4 0.98 35 10
Liquid 95.0 51.9 0.98 22 31
24 h 118.7 112.7 0.97 74 22
14 days 561.8 249.0 0.99 106 13
Liquid 327.5 123.6 0.98 36 15
24 h 312.1 148.4 0.97 54 28
14 days 443.1 260.2 0.99 94 15
Liquid 68.6 103.6 0.98 22 22
24 h 244.6 518.6 0.85 137 15
14 days (-53.2) 1516 0.02 416 27
Liquid 62.2 77.5 0.99 11 16
24 h 72.8 223.7 0.99 37 12
14 days 193.6 457.4 0.99 135 31
Liquid 56.2 103.7 0.90 51 25
24 h 83.8 196.0 0.98 84 29
14 days 131.1 345.8 0.95 237 49
Liquid 105.1 96.3 1.0 49 16
24 h 79.1 140.8 0.96 30 14
14 days 82.1 203.6 0.99 49 17
Liquid 61.4 86.6 1.0 7 8
24 h 48.7 172.2 0.97 80 34
14 days 829.5 867.4 0.98 359 27
Liquid 114.5 138.9 0.99 35 27
24 h 83.3 118.8 0.95 49 14
14 days 91.7 263.1 0.98 55 12
Alexin-HS
Alexin
Dapttin
aPTT-SA
Cephalinex
aPTT-SP
aPTT-P
Platelin LS
SynthASIL
C.K. Prest 2
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FIGURE LEGENDS 
Fig. 1. Thrombin generation assay clotting profiles of Cephalinex in liquid (circles) and 
dried for 24 h (triangles) and 14 days (squares). Blank control was non-activated plasma 
(diamonds) (n = 3).  
 
Fig. 2. The relationship between heparin concentration and CT as calculated using lag 
time (LT) and time to peak (TTP) for aPTT-SP in liquid and dried after 24 h. The trend 
line parameters were found to be as follows: TTP 24h dried (circles) y = 102.32x + 
255.83, R
2
 = 0.986; TTP liquid (reversed triangles) y = 120.77x + 230.94, R
2
 = 0.996; 
LT 24h dried (squares) y = 83.955x + 96.239, R
2
 = 0.986 and LT liquid (diamonds) y = 
116.18x + 88.045, R
2
 = 0.997. 
 
Fig. 3. CT values obtained from plasmas activated with aPTT reagent; liquid (white), 
dried for 24 h (grey) and dried for 14 days (black) (n = 5).  
 
Fig. 4. Relationship between heparin concentration and obtained CT for aPTT-P (n = 5). 
Plasma spiked with heparin (0 – 2 U/mL) was triggered with liquid (circles), 24 h dried 
(reversed triangles) and 14 days dried (squares) reagent. The trend line parameters 
obtained were as follows: y = 62.182x + 77.545, R
2
 = 0.9881, y = 72.818x +223.7, R
2
 = 
0.9883 and y = 193.64x + 457.41, R
2
 = 0.9858 for liquid, 24 h and 14 day dried reagents, 
respectively.  
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